Compare Johnson & Johnson (JNJ) vs Neurocrine Biosciences Inc (NBIX) Price & Performance

Johnson & JohnsonTrade

Neurocrine Biosciences IncTrade

Price performance (Past 24H)

Key statistics

Johnson & Johnson vs Neurocrine Biosciences Inc — how do they compare? Johnson & Johnson trades at $250.8 (market cap $598.96B), while Neurocrine Biosciences Inc trades at $179 (market cap $17.40B). The key difference: Johnson & Johnson is far larger — about 34.4× Neurocrine Biosciences Inc's market cap, and Johnson & Johnson pays a 2.15% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.

	JNJ	NBIX
Market Cap	$598.96B	$17.40B
Volume	6,156,228	—
Sector	Health	Health
52-Week High	$267.24	$180.55
52-Week Low	$164.36	$123.10
Enterprise Value	$631.90B	$16.49B
Dividend Yield	2.15%	—

View details →View details →

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

JNJ

Head and neck squamous cell carcinoma market to grow at 10.5% CAGR by 2036 driven by new immunotherapiesNa · 5 hours agoBullish 2025 tax law boosts US manufacturing jobs, wages, and growth across all 50 statesFox Business · 14 hours agoBullish DIVO ETF up 6.6% YTD but faces pressure from high Treasury yields and low volatility.24/7 Wall Street · 4 days agoNeutral View details →

NBIX

Neurocrine Biosciences appoints Samir Siddhanti as Chief Business Officer to lead growth strategy.PRNewsWire · 6 hours agoBullish View details →

About Johnson & Johnson

Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.

About Neurocrine Biosciences Inc

Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.